Bicyclol in the treatment of patients with chronic diffuse liver diseases

Autor: M. V. Maevskaya, V. D. Lunkov, N. I. Geyvandova, L. K. Palgova, I. Yu. Pirogova, M. K. Prashnova, N. V. Marchenko, E. N. Zinovieva, T. A. Ilchishina, V. T. Ivashkin, P. V. Koroy
Jazyk: ruština
Rok vydání: 2020
Předmět:
Zdroj: Медицинский совет, Vol 0, Iss 15, Pp 78-89 (2020)
Druh dokumentu: article
ISSN: 2079-701X
2658-5790
DOI: 10.21518/2079-701X-2020-15-78-89
Popis: Introduction. The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with morbidity and mortality from liver diseases. Bicyclol has anti-inflammatory and antioxidant effects, which formed the basis for this study.Materials and methods. The study enrolled 51 patients (MELD < 19); hepatitis stage – 84.4%, cirrhosis – 15.6%. Treatment: Bicyclol 75 mg/day for 12 weeks. Criteria of efficacy: dynamics of ALT, AST, CRP; general well-being (D-FIS scale).Results. After 4 weeks of treatment the share of patients with ALT normalization was 50,9% (p < 0,001); with AST normalization – 62.7% (p < 0.001); after 12 weeks - 79,5% and 89,7% respectively (p < 0,001). CRP decreased statistically significantly after 2 and 4 weeks from the beginning of treatment. The D-FIS questionnaire was filled in by 36 patients at the beginning of the study, in 4 weeks - by 35 patients, in 12 weeks – by 32 patients. Median D-FIS decreased from 12 (8.2; 32.2) to 8 (5; 29) points (p < 0,001) after 4 weeks of treatment, after 12 weeks – to 6.5 (3; 28.5) points (p < 0.001). The CRP was positively correlated with the D-FIS value. Fibrosis (“Fibromax”, “Fibroscan”) was studied in 10 additional patients, the dose of Bicyclol was 150/75 mg/day during 6 months, the result was statistically significant (p < 0.001).Conclusion. Application of Bicyclol leads to reduction of fatigue, local and systemic inflammation, fibrosis in chronic diffuse liver diseases regardless of etiology.
Databáze: Directory of Open Access Journals
Externí odkaz: